 |
市场调查报告书
商品编码
1920942
Frost Radar：抗体药物复合体(ADC) 合约开发与生产组织 (CDMO)，2025 年Frost Radar: Antibody-Drug Conjugate Contract Development and Manufacturing Organizations, 2025 |
||||||
一套能够激励企业的标竿体系－推动新业务创建与成长通路的创新
这份Frost Radar™分析了抗体药物复合体(ADC) 合约开发和生产组织 (CDMO) 市场的竞争格局。各公司提供 ADC 所需的生产和开发服务，而 ADC 已成为癌症治疗领域最具活力和价值的治疗方法之一。这场变革癌症治疗的 ADC 革命能否成功，直接取决于本分析中重点介绍的专业 CDMO 的能力。了解这些企业的策略、优势和劣势，对于生物製药产业的所有相关人员至关重要。
为了在充满挑战的环境中取得成功，CDMO（合约研发生产机构）必须提供全面的端到端服务，包括单株抗体生产、高效能药物活性原料药合成、先进的生物偶联以及无菌灌装包装等能力。这些服务必须由先进的设施提供支持，这需要大量的资本投入，以及对管理这些复杂工艺所需的科学和技术人才的同等深度投资。
Frost & Sullivan公司对产业内的众多公司进行分析。公司因其领导力或其他独特特征而被选中，随后根据10项成长和创新标准进行基准测试，从而揭示其在Frost Radar™上的位置。本刊物分析每家公司的优势以及与这些优势最契合的机会，以呈现Frost Radar™竞争概况。
目录
策略要务与成长环境
Frost Radar ™：抗体药物复合体(ADC) 合约开发与生产组织 (CDMO)，2025 年
Frost Radar (TM): C2A（企业行动）
- Abzena
- Ajinomoto Bio-Pharma Services
- Axplora
- Catalent
- ChemExpress
- Lonza
- MabPlex
- Merck KGaA, Darmstadt, Germany
- Piramal Pharma Solutions
- Porton Pharma Solutions
- Recipharm
- Samsung Biologics
- Sterling Pharma Solutions
- Syngene International
- Thermo Fisher Scientific
- WuXi XDC
最佳实践和成长机会
- 最佳实践
- 发展机会
Frost Radar™ 分析
后续步骤：利用Frost Radar™ 赋予关键相关人员
- 登上Frost Radar ™ 的意义所在
- Frost Radar ™ 为 CEO 成长团队赋能
- Frost Radar (TM) 帮助投资者
- Frost Radar ™ 帮助客户
- Frost Radar ™ 支援板
免责声明
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC revolution, which is transforming cancer treatment, is directly dependent on the capabilities of the specialized CDMOs profiled in this analysis. Understanding the strategies, strengths, and weaknesses of these players is essential for any stakeholder in the biopharmaceutical industry.
To succeed in this demanding environment, a CDMO must provide a comprehensive, end-to-end service offering. This includes capabilities in monoclonal antibody production, high-potency active pharmaceutical ingredient synthesis, advanced bioconjugation, and sterile fill-finish drug product manufacturing. These services must be supported by state-of-the-art facilities that require massive capital investment and an equally deep investment in the scientific and technical talent needed to manage these complex processes.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.
Table of Contents
Strategic Imperative and Growth Environment
Frost Radar™: Antibody-Drug Conjugate Contract Development and Manufacturing Organizations, 2025
Frost Radar™: Companies to Action
- Abzena
- Ajinomoto Bio-Pharma Services
- Axplora
- Catalent
- ChemExpress
- Lonza
- MabPlex
- Merck KGaA, Darmstadt, Germany
- Piramal Pharma Solutions
- Porton Pharma Solutions
- Recipharm
- Samsung Biologics
- Sterling Pharma Solutions
- Syngene International
- Thermo Fisher Scientific
- WuXi XDC
Best Practices & Growth Opportunities
- Best Practices
- Growth Opportunities
Frost Radar™ Analytics
Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders
- Significance of Being on the Frost Radar™
- Frost Radar™ Empowers the CEO's Growth Team
- Frost Radar™ Empowers Investors
- Frost Radar™ Empowers Customers
- Frost Radar™ Empowers the Board of Directors
Legal Disclaimer
